SCHEMBL13656398

SCHEMBL13656398

CC(C)CSC(=S)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11448233 0.77 TSHR (0.32)
SCHEMBL10960824 0.74
SCHEMBL4586453 0.72
SCHEMBL27695317 0.72
SCHEMBL9188671 0.70
Potassium Ion SCHEMBL9181470 0.70
SCHEMBL28256051 0.70
SCHEMBL9184975 0.70
Potassium Ion SCHEMBL9186369 0.70
SCHEMBL28255916 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605144-B2 Enzyme catalyzed therapeutic compounds CELMED ONCOLOGY (USA), INC. (CA) 2009-10-20 US disclosed
US-20090069268-A1 NOVEL PHOSPHORAMIDATE COMPOUNDS AND METHODS OF USE CELMED ONCOLOGY (USA), INC. 2009-03-12 US disclosed
US-7462605-B2 Phosphoramidate compounds and methods of use CELMED ONCOLOGY (USA), INC. (CA) 2008-12-09 US disclosed
US-7419968-B1 Methods for treating therapy-resistant tumors CELMED ONCOLOGY (USA), INC. (CA) 2008-09-02 US disclosed
US-20070213307-A1 Methods to treat autoimmune and inflammatory conditions CELMED ONCOLOGY (USA), INC. 2007-09-13 US disclosed